Document is current
Any future updates will be listed below
-
Authors
Pazan, Farhad
Weiss, Christel
Wehling, Martin
,
Denkinger, Michael
von Arnim, Christine
Dovjak, Peter
Frohnhofen, Helmut
Gosch, Markus
Gutzmann, Hans
Hüll, Michael
Iglseder, Bernhard
Kressig, Reto W
Kwetkat, Anja
Schindler, Christoph
Schulz, Ralf-Joachim
Zeyfang, Rom Andrej
Hoffmann, Ute
Drey, Michael
Hardt, Roland
Nau, Roland
Polidori, Cristina
-
Funding
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 24 September 2025
First Online: 21 October 2025
Declarations
:
: Martin Wehling was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, Bayer, Boehringer-Ingelheim, LEO, Mundipharma, Novartis, Pfizer, Polyphor, Helsinn, Allergan, Allecra, Novo-Nordisk, Heel, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie, und Daichii-Sankyo. Farhad Pazan and Christel Weiss have no conflicts of interest to declare.
: The FORTA list containing all relevant data of this survey is available in the supplement.
: N.A.
: N.A.
: N.A.
: N.A.
: Farhad Pazan and Martin Wehling were responsible for the concept, survey planning and execution, evaluation of results, and writing of the article; Christel Weiss performed the statistical analyses and checked the manuscript; all contributors (FORTA group) actively participated in the two-round Delphi survey and sent back the related questionnaire.
